Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer.


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
12 2020
Historique:
received: 04 04 2019
revised: 13 01 2020
accepted: 15 01 2020
pubmed: 19 2 2020
medline: 6 7 2021
entrez: 19 2 2020
Statut: ppublish

Résumé

Observational studies have reported multiple risk factors for pancreatic ductal adenocarcinoma (PDAC). Some are well established, like tobacco smoking, alcohol drinking, obesity and type 2 diabetes, whereas some others are putative, such as allergy and dietary factors. Identifying causal risk factors can help establishing those that can be targeted to contribute to prevent PDAC. We sought to investigate the possible causal effects of established and putative factors on PDAC risk. We conducted a two-sample Mendelian randomisation (MR) study using publicly available data for genetic variants associated with the factors of interest, and summary genetic data from genome-wide association studies of the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4), including in total 8769 cases and 7055 controls. Causality was assessed using inverse-variance weighted, MR-Egger regression and weighted median methods, complemented with sensitivity and radial MR analyses. We found evidence for a causal effect of body mass index (BMI) on PDAC risk (OR 1.43, 95% CI 1.20 to 1.71, p=8.43×10 We found strong evidence that BMI is causally associated with PDAC risk, providing support that obesity management may be a potential prevention strategy for reducing pancreatic cancer risk while fasting insulin and type 2 diabetes showed a suggestive association that should be further investigated.

Sections du résumé

BACKGROUND
Observational studies have reported multiple risk factors for pancreatic ductal adenocarcinoma (PDAC). Some are well established, like tobacco smoking, alcohol drinking, obesity and type 2 diabetes, whereas some others are putative, such as allergy and dietary factors. Identifying causal risk factors can help establishing those that can be targeted to contribute to prevent PDAC.
OBJECTIVE
We sought to investigate the possible causal effects of established and putative factors on PDAC risk.
METHODS
We conducted a two-sample Mendelian randomisation (MR) study using publicly available data for genetic variants associated with the factors of interest, and summary genetic data from genome-wide association studies of the Pancreatic Cancer Cohort Consortium (PanScan) and the Pancreatic Cancer Case-Control Consortium (PanC4), including in total 8769 cases and 7055 controls. Causality was assessed using inverse-variance weighted, MR-Egger regression and weighted median methods, complemented with sensitivity and radial MR analyses.
RESULTS
We found evidence for a causal effect of body mass index (BMI) on PDAC risk (OR 1.43, 95% CI 1.20 to 1.71, p=8.43×10
CONCLUSION
We found strong evidence that BMI is causally associated with PDAC risk, providing support that obesity management may be a potential prevention strategy for reducing pancreatic cancer risk while fasting insulin and type 2 diabetes showed a suggestive association that should be further investigated.

Identifiants

pubmed: 32066631
pii: jmedgenet-2019-106200
doi: 10.1136/jmedgenet-2019-106200
doi:

Substances chimiques

Insulin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

820-828

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Ye Lu (Y)

Genomic Epidemiology Group, DKFZ, Heidelberg, Baden-Württemberg, Germany.
Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.

Manuel Gentiluomo (M)

Department of Biology, University of Pisa, Pisa, Toscana, Italy.

Justo Lorenzo-Bermejo (J)

Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.

Luca Morelli (L)

General Surgery, Department of Surgery, Translational and New Technologies, University of Pisa, Pisa, Toscana, Italy.
EndoCAS (Center for Computer Assisted Surgery), University of Pisa, Pisa, Toscana, Italy.

Ofure Obazee (O)

Genomic Epidemiology Group, DKFZ, Heidelberg, Baden-Württemberg, Germany.

Daniele Campa (D)

Department of Biology, University of Pisa, Pisa, Toscana, Italy daniele.campa@unipi.it.

Federico Canzian (F)

Genomic Epidemiology Group, DKFZ, Heidelberg, Baden-Württemberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH